Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review

Epidemiology of COVID-19 infection in young children under five years: A systematic review and meta-analysis

Mejbah Uddin Bhuiyan a,1,⇑, Eunice Stiboy b,1, Md. Zakiul Hassan c, Mei Chan d, Md. Saiful Islam c,e, Najmul Haider f, Adam Jaffe d,g, Nusrat Homaira d,g

a Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Western Australia, Australia
b School of Public Health, Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia
c Program for Emerging Infections, Infectious Diseases Division, icddr,b, Bangladesh
d School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
e School of Public Health and Community Medicine, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
f The Royal Veterinary College, University of London, Hatfield, Hertfordshire, AL9 7TA, UK
g Respiratory Department, Sydney Children's Hospital, Sydney, New South Wales, Australia

Article info

Article history:
Received 25 August 2020
Received in revised form 16 November 2020
Accepted 30 November 2020
Available online 5 December 2020

Keywords:
COVID-19
Children younger than five years
COVID-19 newborns

Abstract

Introduction: Emerging evidence suggests young children are at greater risk of COVID-19 infection than initially predicted. However, a comprehensive understanding of epidemiology of COVID-19 infection in young children under five years, the most at-risk age-group for respiratory infections, remain unclear. We conducted a systematic review and meta-analysis of epidemiological and clinical characteristics of COVID-19 infection in children under five years.

Method: Following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statements, we searched several electronic databases (PubMed, EMBASE, Web of Science, and Scopus) with no language restriction for published epidemiological studies and case-reports reporting laboratory-confirmed COVID-19 infection in children under five years until June 4, 2020. We assessed pooled prevalence for key demographics and clinical characteristics using Freeman-Tukey double arcsine random-effects model for studies except case-reports. We evaluated risk of bias separately for case-reports and other studies.

Results: We identified 1,964 articles, of which, 65 articles were eligible for systematic review that represented 1,214 children younger than five years with laboratory-confirmed COVID-19 infection. The pooled estimates showed that 50% young COVID-19 cases were infants (95% CI: 36%–63%, 27 studies); 53% were male (95% CI: 41%–65%, 24 studies); 43% were asymptomatic (95% CI: 15%–73%, 9 studies) and 7% (95% CI: 0%–30%, 5 studies) had severe disease that required intensive-care-unit admission. Of 139 newborns from COVID-19 infected mothers, five (3.6%) were COVID-19 positive. There was only one death recorded.

Discussion: This systematic review reports the largest number of children younger than five years with COVID-19 infection till date. Our meta-analysis shows nearly half of young COVID-19 cases were asymptomatic and half were infants, highlighting the need for ongoing surveillance to better understand the epidemiology, clinical pattern, and transmission of COVID-19 to develop effective preventive strategies against COVID-19 disease in young paediatric population.

© 2020 Elsevier Ltd. All rights reserved.
1. Introduction

Globally acute respiratory infection (ARI) including pneumonia is the leading cause of morbidity and mortality in young children aged less than five years. Respiratory viruses such as influenza and respiratory syncytial virus (RSV) remain the leading causes of ARI in under five children [1]. The immature immune system has been linked to increased risk of infectious diseases, particularly respiratory viral infections in infants [1]. However, as the research on ongoing pandemic (Corona Virus Disease 2019 (COVID-19)) caused by a novel respiratory virus, Severe Acute Respiratory Syndrome Coronavirus – 2 (SARS-CoV-2) continues to grow, it appears that young children are less susceptible to this SARS-CoV-2 [2]. Current research suggests that the lowered susceptibility in children is likely due to the scarcity of the SARS-CoV-2 angiotensin-converting enzyme 2 (ACE2) receptor in the respiratory tract in children, meaning that the virus has less receptors to bind to and take hold within a child’s respiratory tract [3]. It is also hypothesised that higher rates of prior infection with other human coronavirus in children may provide protection against severe SARS-CoV-2 infection in children [4]. Additionally, emerging evidence suggest most laboratory confirmed cases of COVID-19 in children results in mild disease, with severe disease in children considered rare [2]. Limited data are available relating to host immunologic response to COVID-19 infection in young children; nevertheless, it is evident that children do get infected with COVID-19 and around 12–18% of infected children are aged < 12 months [5,6]. Few studies have reported potential of transmission of COVID-19 infection from mothers to newborns, but understanding of vertical transmission of COVID-19 infections is still limited [7–10].

As of 28th July 2020, globally there have been 16,646,987 confirmed cases of COVID-19 with 656,608 deaths [11]. The magnitude of the crisis has led to unprecedented speed in developing an effective vaccine. There are nearly 200 candidate vaccines against SARS-CoV-2 infection at different stages of development with at least two being in advanced stages of clinical trial [12]. It is possible that a safe and efficacious vaccine may become available for clinical use by late 2020 or early 2021 [13]. The World Health Organisation (WHO) is working with various stakeholders to ensure that when a vaccine is developed, they will facilitate the equitable access and distribution of the vaccine to people globally, prioritizing people at the greatest risk [14]. Often vaccines for respiratory infections, such as influenza and pneumococcal disease are highly recommended to groups of population at increased risk of severe disease including children aged less than five years, pregnant women, people with chronic morbidities and elderly population (aged > 65 years) [15,16].

At the time of writing this paper (July 2020) the pandemic had been present for 6 months, with many considering this the first wave of the pandemic. According to the US National Center for Biotechnology Information (NCBI) SARS-CoV-2 literature database [17], >35,200 research studies and case reports have been published which provides updated information relating to how the pandemic has evolved in different sub-groups of people in different parts of the world. However, there is a lack of comprehensive epidemiological data relating to the pandemic specifically in children aged less than five years, the most at-risk paediatric age-population for respiratory infections and a priority population for vaccine globally. The objective of this systematic review and meta-analysis was to compile existing literature and analyse published data to provide a robust understanding on epidemiological and clinical pattern of COVID-19 infection in children aged less than five years to inform clinical decisions and guide a road map for prevention strategies including COVID-19 vaccine in young children.

2. Methods

2.1. Search strategy and selection criteria

This systematic review and meta-analyses of available literature on epidemiological and clinical features of COVID-19 infection in children aged less than five years was conducted following standard PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analyses) guidelines. The review protocol was registered in PROSPERO (CRD42020181936).

Relevant articles and reports published as of June 4, 2020 in the electronic databases including Pubmed, EMBASE, Web of Science and Scopus reporting epidemiological and clinical data on laboratory confirmed COVID-19 in children of any age were searched. The search strategy included a combination of free search terms and MESH terms with no language restriction. One review author (MUB) with previous experience of searching literature in electronic databases developed the search strategy. The following terms were included but not limited to the database search: “2019 nCoV”, “2019ncov”, “2019-nCoV”, “2019 novel coronavirus”, “Novel coronavirus 2019”, “COVID 19”, “COVID-19”, “COVID19”, “Wuhan coronavirus”, “Wuhan pneumonia”, “SARS CoV-2”, “SARS-CoV-2” and were limited to “all child (0–18 years)”, and “Human”. Once the initial search was complete, we also looked into WHO coronavirus database to ensure that no relevant key articles were missed. The detailed search strategies applied for different databases are available in Supplementary table 1. EndNote was used to manage literature search output.

The primary eligibility for inclusion of studies were published studies investigating epidemiology, transmission and clinical features of COVID-19 infection in children confirmed by laboratory
| Study | Country | Data collection month | Study design | Total number of < 5 years children with COVID-19 | Age | Male (n) | Reported Source |
|-------|---------|-----------------------|--------------|--------------------------------------------|------|----------|----------------|
| An P [24] | China | Feb | Case report | 1 0 1 | 36 m | 0 | Family |
| Cai J [25] | China | Jan – Feb | Observational | 4 2 2 | 3 m – 60 m | 1 | Community |
| Cai X [26] | China | Jan – Feb | Case report | 4 3 1 | 2 m-15 m | 3 | Family, |
| CDC [27] | USA | Feb – Apr | Observational | 689 398 291 | 0-5y | NA | Community |
| Chen H [28] | China | Jan | Observational | 0 0 | 0 | Newborn | NA | Vertical |
| Chen Y [29] | China | Jan – Feb | Case report | 0 0 | 0 | Newborn | NA | Vertical |
| Cui Y [30] | China | Feb | Case report | 1 1 0 | 55d | 0 | Community |
| Dong L [31] | China | Feb | Case report | 0 0 | 0 | Newborn | NA | Vertical |
| Dong Y [32] | China | Feb | Case report | 223 86 137 | 0-5y | NA | Community |
| Dumpa V [33] | USA | Mar | Case report | 1 1 0 | 22d | NA | Community |
| Jiang S [34] | China | May | Case report | 1 0 1 | 3.5y | 0 | Community |
| Kamali Aghdam M [35] | Iran | Mar | Case report | 1 1 0 | 15d | 0 | Community |
| Kan M [36] | China | Jan | Observational | 0 0 | 0 | Newborn | NA | Vertical |
| Li Y [37] | China | Jan – Feb | Case report | 0 0 | 0 | Newborn | NA | Vertical |
| Liu H [38] | China | Jan – Feb | Observational | 689 398 291 | 0-5y | NA | Community |
| Liu M [39] | China | Jan – Mar | Case report | 2 1 1 | 7 m-2.4y | 1 | Community |
| Liu P [40] | China | Jan – Mar | Observational | 0 0 | 0 | Newborn | NA | Vertical |
| Liu W [41] | China | Jan – Feb | Observational | 689 398 291 | 0-5y | NA | Community |
| Lou X [42] | China | Dec 2019 | Observational | 1 1 0 | 6 m | 1 | Family |
| Lu Y [43] | China | Jan | Observational | 71 31 40 | 1d-5y | NA | Community |
| Ma H [44] | China | Jan – Feb | Observational | 50 NA NA | <2.5y | NA | Community |
| Mao L [45] | China | Dec – Feb | Observational | 1 1 0 | 60 m | 1 | Family |
| Morand A [46] | France | Mar | Case report | 1 1 0 | 15d | 1 | Community |
| Munoz A [47] | USA | Mar | Case report | 1 1 0 | 21d | 1 | Community |
| Nisar N [48] | Pakistan | Jan | Observational | 1 1 0 | 5d-12 | 2 | Community |
| Parveen M [49] | USA | Mar | Case report | 2 2 0 | 25-56d | 2 | Community |
| Peng Z [50] | China | NA | Observational | 10 NA NA | 0-5y | NA | Vertical |
| Qiu H [51] | China | Jan | Observational | 10 NA NA | 0-5y | NA | Family cluster & Community |
| Rahimzadeh G [52] | Iran | NA | Observational | 4 0 4 | 2-3y | 2 | Community |
| Serdar S [53] | Turkey | Jan | Observational | 1 1 0 | 5m | 1 | Family |
| Sarker S [54] | Malaysia | Jan – Feb | Case report | 1 1 0 | 10 d-4y | 1 | Community |
| Shekerdemian L [55] | USA & Canada | Mar – Apr | Observational | 14 8 6 | <1.5y | NA | Community |
| Shen Q [56] | China | Jan | Observational | 1 2 2 | 1m-2y | 0 | Community |
| Song Q [57] | China | Jan | Observational | 4 1 3 | 11-3m | 4 | Community |
| Su L [58] | China | Jan | Observational | 5 2 3 | 11-43 m | 2 | Community |
| Sun D [59] | China | Jan – Feb | Observational | 2 1 2 | 2–25 | 3 | Community |
| Tan Y [60] | China | Jan | Observational | 3 0 3 | 13-3y7m | 1 | Community |
| Wang J [61] | China | Jan | Observational | 1 2 0 | 23d | 1 | Community |
| Wang S [62] | China | Jan | Observational | 1 0 2 | 20-80 | 1 | Community |
| Wei M [63] | China | Dec | Observational | 1 2 0 | 1-11 | 2 | Community |
| Wolf G [64] | Germany | Jan – Feb | Case report | 1 0 1 | 2y | 1 | Community |
| Xia W [65] | China | Jan | Observational | 14 5 9 | 1m-3y | NA | Community |
| Xiong Y [66] | China | Jan | Observational | 1 1 0 | 15y | 1 | Family |
| Xu Y [67] | China | Apr | Observational | 3 2 1 | 2-41 m | 2 | Community |
| Yang H [68] | China | Jan | Observational | 0 0 0 | Newborn | NA | Vertical |
| Yang P [69] | China | Jan | Observational | 0 0 0 | Newborn | NA | Vertical |
| Zachariah P [70] | USA | Mar – Apr | Observational | 12 12 0 | 0-1yr | NA | Community |
| Zeng H [71] | China | Feb | Observational | 0 0 1 | Newborn | NA | Vertical |
| Zeng J [72] | China | Feb | Case report | 1 1 0 | 1y | NA | Community |
| Zhang Q [73] | China | Jan | Case report | 2 1 2 | 14 m | 0 | Community |
| Zhang Y [74] | China | Jan | Case report | 1 1 0 | 3 m | 1 | Community |
| Zhang Z [75] | China | Jan | Observational | 4 4 0 | 30 h–17d | 3 | Family |
| Zheng F [76] | China | Feb | Observational | 10 NA NA | 1 m-3y | NA | Community |
| Zhong Z [77] | China | NA | Observational | 3 1 2 | 1 m-2y | 1 | Community |
| Zhou Y [78] | China | Jan – Feb | Observational | 9 NA NA | 7 m-3y | NA | Community |
| Zhu H [79] | China | Jan | Observational | 0 0 0 | Newborn | NA | Vertical |
| Zhu L [80] | China | Jan – Feb | Observational | 2 0 2 | 1y7m–4y | 2 | Community |

* Data presented where available from selected publications included in the review; NA = Not available.
diagnosis for SARS-CoV-2 from any type of biological specimen (e.g. respiratory specimen, stool etc.) through reverse-transcriptase polymerase chain reaction (RT-PCR), as per the case definition from WHO [18,19]. Only infection of COVID-19 in children confirmed by RT-PCR were included to ensure comparability.

Laboratory diagnosis of SARS-CoV-2 from any type of biological specimen (e.g. respiratory specimen, stool etc.) through reverse-transcriptase polymerase chain reaction (RT-PCR)

Published on or before June 4, 2015.

Exclusion criteria.

Systematic reviews of COVID-19 in children or policy and case-management guidelines or abstracts only or opinion pieces or editorials or letters to the editor.

Studies of children and/or adults where the data for adults and children >5 years could not be excluded.

2.2. Study selection

Two reviewers conducted the initial search (MUB and NH). MUB compiled all articles identified through literature search. Two reviewers (MUB and ES) independently screened the title and abstract of all publications to confirm eligibility and ensured the screened publication reported data for children younger than five years. All publications in Chinese language were translated by one of the investigators (MC) who is a Native Chinese speaker and a health professional (research nurse). Any discrepancies in primary screening were initially discussed by two reviewers and resolved by consensus, otherwise a third reviewer (NH) resolved any disagreements. The risk of reviewer publication bias was minimised by involving two independent reviewers and a third reviewer when required, and by using predefined inclusion and exclusion criteria to identify all relevant studies.

2.3. Data extraction

The following information was extracted from each eligible study: the year of publication, location, study year and timeline, total number of children with COVID-19, average age (median or mean, if both reported, then median was preferred over mean), duration of illness, symptoms (including asymptomatic children), number of children who developed severe illness requiring intensive care unit (ICU) admission and number of deaths. For studies which included both adults and/or children of all ages, only data relating to children younger than five years were extracted.

Extracted data from each publication was recorded in a spreadsheet.

2.4. Data analysis

Risk of bias in the included studies was evaluated using a methodological quality assessment tool formulated by Murad et al. [20] for case series and case reports, and by Hoy et al [21] for all retrospective and prospective studies included in the review. The study characteristics including study design and country were tabulated. The clinical signs and symptoms were categorised under broad clinical headings: a) Upper respiratory included rhinorrhea, cough and blocked or stuffy nose; b) Lower respiratory included tachypnoea and dyspnoea; c) Gastrointestinal included vomiting, diarrhoea, abdominal pain and abdominal distention and, d) Other signs and symptoms that included, headache, poor feeding/decreased oral intake, hypothermia, tachycardia, paroxysmal crying, fatigue/drowsiness and hypotension. Disease severity was classified as mild (no hospitalisation required or discharged from emergency room), moderate (required hospitalisation) or severe (required admission at ICU or high-dependency care unit (HDU) or mechanical ventilation support). Descriptive analysis with available data, was performed on socio-demographic characteristics for children aged less than five years with laboratory-confirmed COVID-19 infection, clinical signs and symptoms, disease severity and outcomes and transmission of SARS-CoV-2 from COVID-19 positive mothers.

The meta-analysis included all studies with the exception of case reports and case series and where n = 1. Pooled estimates on key demographic (age, sex) and clinical characteristics (upper respiratory symptoms, lower respiratory symptoms, other symptoms, disease duration and severity, treatment received) were assessed using Freeman-Tukey double arc sine method, with a random effects model in R statistical software [22]. We intended to estimate the proportion of children aged < 5 years positive among all children who were tested for SARS-CoV-2 infection; however, as there were very few publications where the denominator (total number of children tested for SARS-CoV-2) was reported, proportion positive could not be calculated. Heterogeneity was assessed by Pearson χ² (Q statistic) test and I² statistics was used to report variations [23]. An I² value of < 25% was taken to indicate low heterogeneity. 26%-74% moderate heterogeneity, and > 75% high heterogeneity [23].

3. Results:

3.1. Search outcome and study characteristics

We identified 1,964 articles from electronic databases and manual search (Fig. 1). After removing duplicates (n = 844), titles and abstracts were screened for 1,120 articles and 185 were eligible for full-text examination. Of 185 full-text articles, 65 articles including 39 which were observational studies (retrospective medical record review and prospective cross-sectional studies) and 26 case studies and case reports were included in this review. The main characteristics of the studies are presented in Table 1.

The included 65 studies were conducted in 11 different countries: China (n = 49), United States (n = 6), Iran (n = 2), Vietnam (n = 1), Lebanon (n = 1), Iraq (n = 1), France (n = 1), United Kingdom (n = 1), Australia (n = 1), Canada (n = 1), and Germany (n = 1) (Table 1), and from four different WHO regions (European region, n = 3; Western Pacific region, n = 52 Pacific American region, n = 6; Eastern Mediterranean region, n = 4). Risk of bias was assessed separately for case-reports and case-studies (n = 26) (Fig. 2) and observational studies (n = 39) (Fig. 3). Given the
majority of observational studies included only COVID-19 confirmed children, there was low risk in regard to generalisability to similar paediatric population.

3.2. Demographic features of COVID-19 cases

A total of 1,214 children younger than five years with RT-PCR confirmed COVID-19 infection (further mentioned as COVID-19 cases) were included in this systematic review (Table 1). There were 474 COVID-19 cases from China, 720 from United States of America and Canada, eight from United Kingdom, five from Iran, two from Malaysia and one each from Vietnam, Lebanon, Iraq, France, and Germany. Of 1,214 COVID-19 cases, age-distribution data were available for 1,135 (93%) cases. The age of 1,135 COVID-19 cases ranged from zero days to less than five years: 596 (53%) were less than one year (infant) (Table 1). Among the 596 COVID-19 infant cases, five (1%) were newborns. Of the included 65 studies, 45 studies reported gender distribution for 179 COVID-19 cases: 117 (65%) were male. Source of infection was reported for 1,211 cases, of which 1,186 (98%) cases had a community acquired source.

3.3. Clinical Symptoms, therapeutic management of COVID-19 cases and disease outcome

Of 1,214 COVID-19 cases, symptomatic status was reported for 880 (72%) of children: 834/880 (95%) were symptomatic and 46 (5%) were asymptomatic (Table 2). Where data available, detailed clinical symptoms were extracted for 196 children: fever (75/196, 38%) was the most frequently reported symptom followed by any upper respiratory symptoms (69/196, 35%), gastrointestinal (GI) symptoms were reported in 7.7% (15/196). Disease severity (mild, moderate or severe) were extractable for 345 children: the majority were mild illness (n = 155, 44.9%); 22 cases required simply oxygen therapy and 4 cases required invasive ventilator support. Treatment information was reported for 102 COVID-19 cases. A total of 64 (63%) of COVID-19 cases (20 studies) received at least one antiviral treatment, the most common medications reported were Interferon (includes both interferon beta-1b and interferon alfa-2b) (n = 31, 47.7%) and Oseltamivir (n = 20, 30.8%). Similarly, antibiotic treatments were reported in 17 studies and 29 COVID-19 cases (29%) received at least one antibiotic, with the most commonly reported antibiotic being Azithromycin (n = 8, 27.6%). Steroid treatment was reported in nine cases: all received Methylprednisone.

Disease outcome was reported for 121 cases (43 publications), of these cases 120 cases were discharged from hospital or recovered with one death. The deceased case was a 10 month-old female infant with no underlying medical conditions or no history of preceding exposure to a known COVID-19 case [26].

3.4. COVID-19 infection in newborns from COVID-19 infected mothers

Of the 65 publications included in the review, 14 reported SARS-CoV-2 status in 151 newborns from 149 laboratory-confirmed or clinically-confirmed COVID-19 positive mothers, all
were diagnosed with COVID-19 prior to delivery [28,29,31,39,42,43,57,68,74–76,78,82,86]. Of the 149 deliveries, 133 (89%) were caesarean section (C-section) (Supplementary table 2). Of the 151 babies born, 25 (16.5%) were born preterm (gestational age < 37 weeks) and 15 (10%) had low-birth weight (<2500 g). Five (3.3%) newborns were COVID-19 positive by RT-PCR at age 30 h to 17 days. All the five mothers completed at least 40 weeks of gestation and all five newborns were delivered by C-section. All but one mother developed respiratory symptoms before delivery. Of five newborns, three of them showed at least one respiratory symptom including fever, cough, shortness of breath and vomiting. None of them required intensive care unit admission or mechanical ventilation. The hospital stays of newborns ranged from 16 days to 30 days.

3.5. Meta-analysis

A total of 31 studies (COVID-19 cases, n = 1,181) (excluding case-reports and case-studies) were eligible for meta-analysis, studies excluded from the meta-analysis included studies were n = 1. Using data, when available, the outputs from meta-analysis are presented in Table 3. The pooled estimate showed that among children aged less than five years with COVID-19 infection, 50% (95% CI: 36% to 63%) of children were aged less than one year (Fig. 4) and 53% (95% CI: 41% to 65%), were male (supplementary Fig. 1). Using studies that reported both symptomatic and asymptomatic COVID-19 cases, the pooled prevalence showed 43% (95% CI: 15% to 73%) were asymptomatic. We estimated 40% (95% CI: 6% to 78%) required no hospitalisation. Of the children who required hospitalisation (moderate/severe disease), 49% (95% CI: 12% to 86%) required oxygen therapy (not inclusive of mechanical ventilation). The pooled prevalence for antiviral treatment was 99% (95% CI: 92% to 100%) using data from 10 studies comprising 48 COVID-19 cases and similarly, for antibiotics was 71% (95% CI: 46% to 92%) using data from 5 studies comprising 14 COVID-19 cases, many cases reported combined treatments.

### Table 2

Descriptive clinical characteristics of 1,214 RT-PCR confirmed COVID-19 cases for all 65 articles included in review.

| Number of children (N) |   |
|------------------------|---|
| Symptomatic status     |   |
| Symptomatic            | 880 (94.7%) |
| Asymptomatic           | 46 (5.2%)  |
| Symptoms reported a    |   |
| Fever                  | 196 (38.2%) |
| Upper Respiratory      | 69 (35.2%) |
| Lower Respiratory      | 10 (5.1%)  |
| Gastrointestinal       | 15 (7.7%)  |
| Other                  | 27 (13.8%) |
| Disease Severity b     |   |
| Mild                   | 155 (44.9%) |
| Moderate               | 173 (50.1%) |
| Severe                 | 17 (4.9%)  |
| Medications            |   |
| Antivirals c           | 64 (62.7%) |
| Antibiotics d          | 29 (28.4%) |
| Steroids               | 9 (8.8%)   |
| Disease Outcomes       |   |
| Recovered/Discharged   | 120 (99.2%) |
| Dead                   | 1 (0.8%)   |
| Source                 |   |
| Community              | 1186 (97.9%) |
| Family                 | 12 (0.9%)  |
| Vertical               | 13 (1.2%)  |

a Upper respiratory symptoms included rhinorrhoea, cough and blocked or stuffy nose; Lower respiratory symptoms included tachypnoea and dyspnoea; Gastrointestinal symptoms included vomiting, diarrhoea, abdominal pain and abdominal distention; Other symptoms that were reported in few cases included, headache, poor feeding/decreased oral intake, hyperthermia, tachycardia, paroxysmal crying, fatigue/drowsiness and hypotension;
b Mild Disease = non-hospitalised, Moderate Disease = hospitalised, Severe Disease = HDU/ICU admission/mechanical ventilation.

c Interferon (n = 31), Oseltamivir (n = 20), Ritonavir (n = 9), Lopinavir (n = 7), Ribavirin (n = 7), Chloroquine (n = 4) and lopinavir (n = 2).
d Azithromycin (n = 8), Meropenem (n = 5), Vancomycin (n = 4), Linezolid (n = 2), Augmentin (n = 2), Gentamicin (n = 2), Ampicillin (n = 1), Cefepime (n = 1), Penicillin (n = 1), Ceftriaxone (n = 1), Amikacin (n = 1), Cefotaxime (n = 1), Amoxicillin (n = 1), Ceftazidime (n = 1, 3.4%).
for patients. We were unable to extract data on transmission source and death for the meta-analysis.

4. Discussion:

To our knowledge this is the most comprehensive systematic review and meta-analysis of the literature, specific for children aged less than five years with laboratory confirmed COVID-19 infection. Our systematic review suggests that the prognosis of COVID-19 in children aged less than five years aligns with current published research, with >90% of children developing mild to moderate disease. These results are similar to recent reviews by Castagnoli et al [88] and Hoang et al [89] in all children < 18 years. This also follows trends that only 7% of cases in our review were severe cases requiring ICU or HDU admission, compared to 53% of adults recorded with severe COVID-19 disease requiring ICU admission [90]. This is a particularly important finding given that infants and young children aged less than five years are already at high risk of severe disease associated with other respiratory infections including influenza and RSV. It is likely that many COVID-19 infections in young children were classified as moderate illness (requiring hospital admission), were in fact mild disease, as those reported to have a hospital admission were due to isolation requirements only, not necessarily due to severity of clinical condition. This is also likely that many asymptomatic children were not tested and thus only the children with clinical manifestations were included in this study. Thus, the proportions we reported for severe and moderate cases could be higher than the true proportions.

Emerging data suggest that children with confirmed and suspected COVID-19 infection can present with Kawasaki-like syndrome which has been termed as multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 [91–93]. While such inflammatory syndrome has been documented in paediatric population in the United States, United Kingdom and also Italy, in our systematic review we did not find any reports of Kawasaki disease like syndrome or MIS-C in COVID-19 cases < 5 years to be included in this systematic review.

This systematic review of >1,200 children aged less than five years with COVID-19 infection showed half of these cases were aged less than one year. Infants are particularly at higher risk of infectious disease during the first few months of their lives due to the inadequately developed immune system and are often targeted for prevention strategies. We also found that a handful of newborns (<4%) from COVID-19 infected mothers had laboratory confirmed COVID-19 infection within several hours to days of birth. Nonetheless, the vertical transmission of COVID-19 remains unclear as none of those studies could persuasively claim mother to neonate transmission. Recent reviews addressing immunological assessment, concluded with no evidence of intrauterine transmission during delivery from mothers to their fetuses [9,42,94]. These findings are analogous to data reported during previous influenza pandemics and novel coronavirus strains, associated with Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) epidemics [95,96]. Vaccine remains one of the most effective public health interventions to prevent transmission of infectious diseases. However, the immature immune system of newborns also...
Table 3
Meta-analysis of outcomes (random effects model)a

| No. of Studies | Proportion 95%CI b | Total no. of cases (n) | I² c | I² c | Q | P-value c |
|----------------|---------------------|------------------------|------|------|---|---------|
| **Age**        |                     |                        |      |      |   |         |
| <1yr           | 27                  | 0.50 0.36 – 0.63       | 580  | 78.9% | 0.0379 | 123.17 | <0.0001 |
| 1–5 yr         | 27                  | 0.50 0.37 – 0.64       | 523  | 78.9% | 0.0379 | 123.17 | <0.0001 |
| **Sex**        |                     |                        |      |      |   |         |
| Male           | 24                  | 0.53 0.41 – 0.65       | 78   | 20.4% | 0.0104 | 28.88  | 0.1844  |
| **Clinical Characteristics** |       |                        |      |      |   |         |
| Asymptomatic Cases | 9       | 0.43 0.15 – 0.73       | 42   | 82.7% | 0.1152 | 46.24  | <0.0001 |
| Symptomatic Cases  | 11      | 0.56 0.008 – 1.00     | 714  | 99.4% | 0.7045 | 1588.73 | 0       |
| **Symptoms reported** |      |                        |      |      |   |         |
| Fever          | 18                  | 0.76 0.61 – 0.89       | 43   | 0.0%  | 0      | 14.70  | 0.2175  |
| Upper Respiratory Symptoms | 13     | 0.75 0.55 – 0.93       | 37   | 25.3% | 0.0182 | 16.05  | 0.1887  |
| Lower Respiratory Symptoms | 2      | 0.34 0.03 – 0.72       | 4    | 0.0%  | 0      | 0.00   | 0.9545  |
| Gastrointestinal Symptoms | 3      | 0.73 0.20 – 1.00       | 7    | 48.7% | 0.0772 | 5.85   | 0.1192  |
| Other Symptoms  | 2                   | 0.97 0.54 – 1.00       | 10   | 32.5% | 0.0399 | 2.96   | 0.2272  |
| **Treatment**  |                     |                        |      |      |   |         |
| Antibiotics    | 5                   | 0.71 0.46 – 0.92       | 14   | 5.4%  | 0.0032 | 4.23   | 0.0375  |
| Antivirals     | 10                  | 0.99 0.92 – 1.00       | 48   | 0.0%  | 0      | 6.11   | 0.4291  |
| Steroids       | 3                   | 0.65 0.30 – 0.93       | 7    | 0.0%  | 0      | 0.88   | 0.0438  |
| Oxygen Therapy d | 7       | 0.49 0.11 – 0.87       | 14   | 78.2% | 0.1489 | 27.58  | 0.0001  |
| **Disease Severity** |       |                        |      |      |   |         |
| Mild           | 4                   | 0.40 0.06 – 0.78       | 132  | 84.1% | 0.0990 | 18.91  | 0.0003  |
| Moderate       | 7                   | 0.51 0.16 – 0.85       | 98   | 87.9% | 0.1449 | 49.75  | <0.0001 |
| Severe         | 5                   | 0.07 0.00 – 0.30       | 9    | 73.5% | 0.0545 | 15.08  | 0.0045  |
| **Disease duration (days)** |   |                        |      |      |   |         |
| Duration of illness | 8      | 3.00 – 3.10            | 30   | 6.51  | 10     | 33.1   |
| Duration between symptom onset to detection | 9      | 2.06 – 1.79            | 43   | 2.06  | 1.79   | 7.02   |
| Duration of hospital stay | 5      | 4.08 – 8.22            | 24   | 4.08  | 8      | 22.27  |

a Data presented in meta-analysis is only from 31 studies with available data (excluded case reports).
b 95%CI = 95% Confidence Interval.
c P-value correspondsto Q test statistic and heterogeneity assessment of studies.
d Not inclusive of mechanical ventilation.
e Mean calculated as weighted average.

Fig. 4. Forest plot of proportion of all COVID-19 positive children (aged < 5 years) who were aged less than one year from 31 studies included in meta-analysis.
makes them unsuitable for many vaccines. Maternal immunization during pregnancy has been proven to be an effective strategy in providing protection to infants, against many vaccine-preventable diseases including pertussis, tetanus and influenza during the first few months of life. Maternal immunization during pregnancy has two benefits, it protects the mother and fetus and it also protects the newborn through transplacental transfer of maternal antibody [97]. To date, we do not have an effective vaccine against COVID-19, but there are several vaccines in advanced clinical stages that may become available for clinical use within next 6–12 months [12]. In a situation where the COVID-19 vaccination is deemed to be unsuitable for infants, maternal immunisation could be a viable preventive approach.

We found the majority (>95%) of the COVID-19 infections in children reportedly had a community source of infection, however, familial clusters were common in four case reports included in the review. Young adults and children have a high likelihood of developing COVID-19 due to household transmission, once a family member tests positive to COVID-19 [24]. However, there is limited evidence of secondary infection from children to others, suggesting that the role children play in the transmission pathways of COVID-19 remains unclear. Longer duration of virus shedding through the gastrointestinal tract can play a role in potential faecal-oral transmission of the virus, however this is yet to be confirmed [72,73].

Our systematic review suggests while many children younger than five years were treated with antivirals, 71% were treated with antibiotics, despite having a confirmed diagnosis of COVID-19. This is a concerning proportion of antibiotic use as a treatment for the viral disease in children, given the inappropriate use of antibiotics in under five children is a significant contributor to the emergence and spread of antimicrobial resistance globally [101,99]. While prophylactic treatment with antibiotics in infants with unknown source of infection, is routine in preventing bacteraemia, urinary tract infection (UTI) or pneumonia, this still has limitations in populations of increased antimicrobial resistance [100,101].

4.1. Strengths and limitations

The major strength of our study is it provides comprehensive epidemiological and clinical data on COVID-19 infection in a very specific age-group of children considered to be at highest risk of morbidity and mortality associated with ARIs including pneumonia. We were able to include available and eligible literature that were published in Chinese language (n = 17) during the very early stage of pandemic and inclusion of these articles added to the evidence base of this systematic review. Additionally, this allowed us to include a large number of young children (n = 1,214) in our analysis further strengthening the review.

However, our review had some important limitations as well. The final search of the databases was concluded in early June, which meant that many geographical regions such as the United States and Europe that had resurgence of COVID-19 cases during a second wave were not included in our review. Nevertheless, as more literature become available, our systematic review will provide a comprehensive evidence base to further investigate epidemiological and clinical pattern of COVID-19 in children aged < 5 years. We had 26 case reports and hence the data could not be used in our meta-analysis which might have impacted the generalisability of the results. Additionally, only few studies provided detailed information on clinical outcome of the disease, which could be extracted for the pooled analysis. Hence, high level of heterogeneity was observed for some of the key clinical variables in the meta-analysis. In order to incorporate the between-study variations, random effect models were used to estimate the summary effect size. There were only two studies from two European countries other than United Kingdom and none from Italy, Sweden, or Spain where the impact of pandemic has been extensive. In our search, we could not find any eligible studies from any country in the South East Asian Region (SEARO) region, where the response to the pandemic capacities remain insufficient. These areas are of particular concern as they tend to have a higher burden of childhood ARI. Additionally, we did not find articles reporting COVID-19 in Indigenous or ethnic minority paediatric populations although these groups of children have higher risk of respiratory infections. Lastly, even though we used comprehensive mesh terms for searching, it is possible we missed some articles.

4.2. Conclusions

Our systematic review has shown that young children aged less than five years generally develop mild COVID-19 disease and these infections are often acquired through community sources. Half of the children aged less than five years with COVID-19 infection were infants. Additionally, a large proportion of the young children with COVID-19 infection are asymptomatic, underpinning the need for ongoing surveillance to monitor COVID-19 disease epidemiology in this paediatric population, strengthening prompt laboratory identification for case isolation and clinical management. Future research to understand risk of vertical transmission of COVID-19 infection will help guide policy decisions around maternal vaccination when an effective vaccine becomes available.

Funding
None

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.vaccine.2020.11.078.

References

[1] Tregoning JS, Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev 2010;23 (1):74–98.
[2] Steinman JB, Lum FM, Ho PP, Kaminski N, Steinman L. Reduced development of increased antimicrobial resistance[100,101].
[3] Carsetti R, Quintarelli C, Quinti I, et al. The immune system of children: the task of the virologist in the fight against viruses. Hum Immunol 2019;80 (4):285–91.
[4] Ng, KW, Faulkner N, Cornish GH, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science 2020;368 (6480). https://doi.org/10.1016/j.vaccine.2020.11.078.
[5] Carsetti R, Quintarelli C, Quinti I, et al. The immune system of children: the key to understanding SARS-CoV-2 susceptibility?[1]. The Lancet Child & Adolescent Health. 2020;4(5):414–6.
[6] With, Coronavirus Disease in China. Pediatrics 2019;2020:e20200702.
[7] Dong Y, Mo X, Hu Y. Epidemiological Characteristics of 2143 Pediatric Patients With, Coronavirus Disease in China. Pediatrics 2019;2020:e20200702.
[8] Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. 2020;382 (17):1663–5.
[9] Hu X, Gao J, Luo X, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vertical Transmission in Neonates Born to Mothers With Coronavirus Disease 2019 (COVID-19) Pneumonia. Obstet Gynecol 2020;136 (1):65–7.
[10] Aizamora MC, Paredes T, Caceres D, Webb CM, Valdez LM, La Rosa M. Severe COVID-19 during Pregnancy and Possible Vertical Transmission. Am J Perinatol 2020;37(8):861–5.
[11] Karimi-Zarchi M, Neamatizadeh H, Dastgheib SA, et al. Vertical Transmission of Coronavirus Disease 19 (COVID-19) from Infected Pregnant Mothers to Neonates: A Review. Fetal Pediatr Pathol. 2020;39(3):246–50.
[12] Schwartz DA, Graham AL. Potential maternal and infant outcomes from (Wuhan) Coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections. Viruses 2020;12 (2):194. https://doi.org/10.3390/v120200.
Yang H, Hu B, Zhan S, Yang LY, Xiong G. Effects of SARS-CoV-2 infection on pregnant women and their infants: A retrospective study in Wuhan, China. Archives of pathology & laboratory medicine. 2020.

Yang F, Wang X, Liu P, et al. Clinical characteristics and risk assessment of newborns born to mothers with COVID-19. J Clin Virol 2020;127.

Zachariah P, Halabi KC, Johnson CL, Whitter S, Sepulveda J, Green DA. Symptomatic Infants have Higher Nasopharyngeal SARS-CoV-2 Viral Loads but Less Severe Disease than Older Children. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020.

Zeng H, Xu C, Fan J, et al. Antibodies in Infants Born to Mothers with COVID-19 Pneumonia. JAMA - J Am Med Assoc 2020;323(1):e1–2.

Zeng H, Xu C, Fan J, et al. Antibodies in Infants Born to Mothers with COVID-19 Pneumonia. JAMA - J Am Med Assoc 2020;323(1):e1–2.

Zhang YH, Lin DJ, Xiao MF, et al. [2019 novel coronavirus infection in a three-month-old baby]. Zhonghua er ke za zhi = Chinese journal of pediatrics. 2020;58(3):182–4.

Zhong Z, Xie X, Huang W, Zhao W, Yu Q, Liu J. Chest CT findings and clinical features of coronavirus disease 2019 in children. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics. 2020;22(3):215–20.

Zhou Y, Yang GD, Feng K, et al. [Clinical features and chest CT findings of coronavirus disease 2019 in infants and young children]. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics. 2020;22(3):215–20.

Zhao J, Wang X, Huang R, et al. Clinical characteristics of a case series of children with coronavirus disease 2019. Pediatr Pulmonol 2020;55(6):1430–2.